page contents

FDA approves Mylotarg for treatment of acute myeloid leukemia

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).

Mylotarg originally received accelerated approval in May 2000 as a stand-alone treatment for older patients with CD33-positive AML who had experienced a relapse. Mylotarg was voluntarily withdrawn from the market after subsequent confirmatory trials failed to verify clinical…
Cancers – Healthcanal.com

PLEASE CLICK ON PUBLISHER AT THE END OF TEXT TO READ THE COMPLETE ARTICLE...

Leave a Reply

Your email address will not be published. Required fields are marked *

*